Literature DB >> 16612142

Establishing a minimal erythema concentration of methyl nicotinate for optimum evaluation of anti-inflammatories.

L C Jumbelic1, F T Liebel, M D Southall.   

Abstract

Topical administration of chemicals such as methyl nicotinate that induce erythema have been employed to measure the effectiveness of formulations containing anti-inflammatory agents. Prior studies have utilized a single concentration of methyl nicotinate, between 36.5 and 100 mM, for all test subjects in evaluations of topical formulations. However, individuals have different thresholds of response to methyl nicotinate; thus, a single concentration may not be appropriate for all individuals and could result in the apparent lack of anti-inflammatory activity of the formulation being evaluated. In the current study, we evaluated the use of a minimal erythema concentration (MEC) of methyl nicotinate, defined as the lowest concentration that produces a complete and even erythema at the test site, compared with a 36.5-mM concentration of methyl nicotinate. Hydroalcoholic gels containing the nonsteroidal anti-inflammatory drug ibuprofen were compared with placebo. Diffuse reflectance spectroscopy was employed to measure differences in cutaneous inflammatory response between the control (placebo)-treated group and the ibuprofen-treated group. When chemical erythema was induced using an MEC of methyl nicotinate, greater reductions in erythema were seen in ibuprofen-treated sites compared with sites treated with a 36.5-mM concentration of methyl nicotinate. In conclusion, for an accurate assessment method of erythema induced by methyl nicotinate, consideration should be given to determining the extent of response of an erythema-producing agent on an individual basis. An MEC of methyl nicotinate should be determined and employed for each individual to obtain more consistent and reliable efficacy results of anti-inflammatory activity. 2006 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16612142     DOI: 10.1159/000092595

Source DB:  PubMed          Journal:  Skin Pharmacol Physiol        ISSN: 1660-5527            Impact factor:   3.479


  2 in total

1.  Achieving Biocompatible SABRE: An in vitro Cytotoxicity Study.

Authors:  Anand Manoharan; Peter J Rayner; Wissam Iali; Michael J Burns; V Hugh Perry; Simon B Duckett
Journal:  ChemMedChem       Date:  2018-01-18       Impact factor: 3.466

2.  Stability of methylnicotinate in aqueous solution as utilized in the 'niacin patch test'.

Authors:  Brian M Ross; Martin Katzman
Journal:  BMC Res Notes       Date:  2008-09-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.